The effects of XEN-D0501 on cough frequency in COPD patients

• Research type

  Research Study

• Full title

  A double-blind, randomised, placebo-controlled, crossover study to assess the efficacy of XEN-D0501, a TRPV1 antagonist, in reducing the frequency of cough in patients with chronic obstructive pulmonary disease.

• IRAS ID

  140346

• Contact name

  Jaclyn Smith

• Contact email

  jacky.smith@manchester.ac.uk

• Sponsor organisation

  Xention Limited

• Eudract number

  2013-004041-17

• Research summary

  This is a phase 2a double-blind, randomised, placebo-controlled crossover study that will assess the efficacy of XEN-D0501, a TRPV1 antagonist, in reducing the frequency of cough in patients with chronic obstructive pulmonary disease. 24 hour cough monitoring, daily cough diaries and clinical questionnaires will be used as efficacy variables.

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  13/NW/0741

• Date of REC Opinion

  3 Dec 2013

• REC opinion

  Further Information Favourable Opinion